Head-to-head comparison
| Property | Melanotan II | PT-141 |
|---|---|---|
| Category | Skin & Beauty | Sexual Health |
| Legal Status | Unregulated | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~1 hour | ~2.7 hours |
| Mol. Weight | 1,024.18 Da | 1,025.18 Da |
| Side Effects | Nausea (common initially), Facial flushing, Fatigue | Nausea (40%), Flushing (20%), Headache |
Key differences
- Mechanism: Melanotan II binds non-selectively to melanocortin receptors MC1R through MC5R; PT-141 primarily activates MC4R in the hypothalamus for sexual arousal effects with reduced melanocortin receptor cross-activity.
- Legal status: PT-141 is FDA-approved as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women; Melanotan II is not FDA-approved and has received regulatory warnings from the FDA, TGA, and MHRA.
- Primary use: Melanotan II is used primarily for skin tanning via MC1R-mediated melanogenesis; PT-141 is used for sexual desire enhancement via central MC4R activation.
- Side effects: Melanotan II causes nausea, facial flushing, new or darkened moles, spontaneous erections, and appetite suppression; PT-141 causes nausea (40%), flushing (20%), headache, and transient blood pressure increases.
- Dosing: Melanotan II is dosed at 250-500 mcg daily during a loading phase, then 1-2x weekly for maintenance; PT-141 is dosed at 1.75 mg as needed (max 1 dose per 24 hours, max 8 per month).
- Evidence base: PT-141 has Phase III trial data (RECONNECT) supporting FDA approval; Melanotan II has Phase II data showing tanning efficacy but no completed path to regulatory approval.
- Half-life: Melanotan II has a half-life of approximately 1 hour; PT-141 has a half-life of approximately 2.7 hours.
The verdict
PT-141 represents a more targeted refinement of the melanocortin signaling that Melanotan II activates broadly. PT-141 has the advantage of FDA approval and Phase III clinical evidence for sexual desire, while Melanotan II remains unregulated with broader receptor activity that produces both tanning and sexual effects along with a wider side effect profile. For sexual health specifically, PT-141 has stronger clinical validation. Melanotan II remains more commonly used for tanning, a use that PT-141 was not designed to serve.
Frequently asked questions
Yes. PT-141 (bremelanotide) was developed when University of Arizona researchers observed that Melanotan II produced sexual arousal as a side effect. PT-141 was specifically engineered to isolate the MC4R-mediated sexual function effects while reducing the tanning and other melanocortin effects, though some melanogenesis can still occur.
Yes, Melanotan II activates MC4R (among other melanocortin receptors), which produces sexual arousal effects in both men and women. This was a consistent finding in clinical studies. However, its non-selective receptor binding causes additional effects including tanning, appetite suppression, and nausea that PT-141 was designed to minimize.
PT-141 can produce some melanogenesis because it retains low-level activity at MC1R, though this effect is substantially less pronounced than with Melanotan II. PT-141 was developed specifically to isolate the sexual function effects from the tanning effects of its precursor.
Melanotan II has a broader side effect profile due to its non-selective binding across MC1R-MC5R, including new or darkened moles, spontaneous erections, and appetite suppression in addition to nausea and flushing. PT-141's side effects are primarily nausea (40%), flushing (20%), and headache, with fewer off-target effects.
PT-141 is generally considered better characterized for sexual health use, with FDA approval based on Phase III trials and a defined safety profile. Melanotan II has limited long-term safety data, potential mole changes that complicate skin cancer screening, and broader receptor activity producing more off-target effects. PT-141 underwent formal safety evaluation that Melanotan II did not.